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P ulmonary tumor thrombotic microangiopathy (PTTM),  a rare clinicopathological entity causing 
pulmonary hypertension in cancer patients,  was first 
reported by von Herbay et al.  in 1990 [1].  There are 
several reports of PTTM from Japan where the preva-
lence of gastric cancer is high,  because gastric cancer is 
the malignancy that is most commonly associated with 
PTTM [2].  We report the fourth case of PTTM origi-
nating from metastatic prostate cancer.
Case Presentation
An 81-year-old Japanese man with a history of old 
myocardial infarction and chronic obstructive pulmo-
nary disease had been clinically diagnosed with prostate 
cancer approx.  8 years prior to his present admission 
(serum prostate-specific antigen [PSA] level 51.3 ng/mL,  
clinical stage T3bN0M0) and was treated with com-
bined androgen blockade.  However,  the disease pro-
gressed gradually over the next 7 years and became 
castration resistant.  Radiological assessment revealed 
multiple bone metastases.  Although we recommended 
chemotherapy,  he voluntarily discontinued his fol-
low-up visits.  Six months later,  he was admitted to our 
hospital with dyspnea of a few days’ duration,  and loss 
of appetite that started 2 months previously.
On admission,  the patient was afebrile,  with a 
blood pressure at 154/71 mmHg and a heart rate of 
80 beats/min.  Peripheral oxygen saturation was 90% on 
room air.  His PSA level was highly elevated at 
696.2 ng/mL; alkaline phosphatase was 7,672 U/L,  
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Pulmonary tumor thrombotic microangiopathy (PTTM) is a fatal,  malignancy-related respiratory complica-
tion; we herein report a PTTM case induced by metastatic prostate cancer.  An 81-year-old Japanese man 
developed dyspnea.  High-resolution computed tomography (HRCT) revealed ground-glass opacities spread 
across bilateral lung fields.  Pulmonary microvascular aspiration cytology detected prostate cancer cells.  As 
PTTM was highly suspected,  docetaxel chemotherapy was performed immediately.  His respiratory condition 
and HRCT findings improved temporarily,  but he died approx.  6 weeks after admission.  Autopsy showed 
fibrocellular intimal proliferation of small pulmonary arterioles,  which confirmed the diagnosis of PTTM 
induced by prostate cancer.  As in the present case,  it is often difficult to confirm the presence of not only tumor 
embolization but also fibrocellular intimal proliferation before the patient’s death.
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fibrin degradation product was 31 μg/dL,  and the 
D-dimer level was 9.5 μg/dL.  Arterial blood gas mea-
surement indicated hypoxemia (PaO2 50.0 mmHg and 
PaCO2 32.0 mmHg) on room air.  An electrocardio-
gram showed complete right bundle branch block.  The 
tricuspid regurgitation pressure gradient shown by 
echocardiogram was 34 mmHg (normal,  < 30 mmHg),  
suggesting pulmonary hypertension.
Chest radiography demonstrated ground-glass 
opacities (GGOs) and patchy shadows on both bilateral 
middle and lower lung fields.  Contrast-enhanced 
high-resolution computed tomography (HRCT),  which 
had previously shown only emphysema change,  
revealed the progression of diffuse bone metastases and 
GGOs as well as micronodular opacities diffusely spread 
across bilateral lung fields (Fig. 1); however there was 
no evident pulmonary embolism.  Lung perfusion scin-
tigraphy showed bilateral multiple subsegmental defects 
(Fig. 2).  On right heart catheterization on Day 8,  the 
mean pulmonary arterial pressure was elevated to 
21 mmHg but did not meet the criteria for pulmonary 
hypertension (mean pulmonary artery pressure 
≥ 25 mmHg).
PSA stain-positive adenocarcinoma was detected by 
pulmonary microvascular aspiration cytology.  This 
finding suggested that the cells originated from the 
prostate cancer (Fig. 3).  On transbronchial lung biopsy 
(TBLB),  tumor cells were detected in small vessels in 
the stromal tissue (Fig. 4).  Pulmonary embolism caused 
by tumor or thrombosis,  and lymphangiosis carcino-
matosa were differential diagnoses based on these find-
ings.  A definitive diagnosis was difficult to determine at 
that time.  However,  we strongly suspected PTTM 
induced by prostate in light of the following: the rapid 
progressive dyspnea,  hypoxemia,  the marked increase 
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Fig.  1　 Chest HRCT scan on admission showed GGOs,  small 
granular shadows,  consolidations,  and bronchial wall thickenings in 
bilateral lungs diﬀusely.
Fig. 2　 Lung perfusion scintigraphy showed multiple subsegmen-
tal defects.
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Fig.  3　 Pulmonary microvascular cytology detected PSA stain-positive adenocarcinoma.
in PSA,  the hypercoagulable condition,  the tendency of 
increasing pulmonary artery pressure,  no macroscopic 
pulmonary tumor emboli in the contrast-enhanced CT,  
multiple subsegmental defects shown by lung perfusion 
scintigraphy,  the presence of PSA stain-positive adeno-
carcinoma detected by TBLB,  and the pulmonary aspi-
ration cytology results.
Therefore,  chemotherapy with docetaxel (55 mg/m2) 
on Day 10 was performed for prostate cancer.  At the 
time,  the patient’s only subjective symptom was dys-
pnea on exertion,  and his oxygen saturation level was 
approx.  95% on 4 L/min of O2.  Immediately after che-
motherapy,  his condition improved somewhat.  His 
oxygen saturation level increased to approx.  98% at rest 
on 4 L/min of O2.  The oxygen dose could not be 
decreased,  because of oxygen desaturation on exertion.  
On Day 28,  HRCT revealed the improvement of the 
GGOs and micronodular opacities (Fig. 5),  and the tri-
cuspid regurgitation pressure gradient by echocardio-
gram decreased from 34 mmHg to 30 mmHg.  
Nevertheless,  the patient’s general condition had grad-
ually worsened due to febrile neutropenia on Day 18,  
and pseudomembranous enterocolitis was observed on 
Day 21.  After each improvement was observed,  we 
debated the necessity of administering additional che-
motherapy,  and the second round with docetaxel 
(37 mg/m2) was performed on Day 38.  Nevertheless,  
the patient’s respiratory status deteriorated rapidly on 
Day 40,  and he died of the primary disease on Day 41.
On autopsy,  the patient’s lungs showed bilateral 
congestive edema; however tumor lesions on the mac-
roscopic cut surface and inflammation of the lungs were 
not detected.  The histological examination of the lung 
revealed tumor emboli from prostate cancer,  fibrocel-
lular intimal proliferation,  and stenosis and recanaliza-
tion at the lung arterioles (Fig. 6).  A definitive diagnosis 
of PTTM derived from prostate adenocarcinoma was 
made based on the autopsy findings.
Discussion
PTTM,  which is characterized by microscopic 
tumor embolization and fibrocellular intimal prolifera-
tion of small pulmonary arterioles,  has a poor progno-
sis.  The mean time from the onset of dyspnea to death 
is reported only 3-4 weeks [3 , 4].  In the present case,  
the period from the appearance of symptoms to death 
was 6 weeks.  We believe that the early treatment due to 
suspected illness contributed to the improvement of his 
symptoms and CT findings,  and to the prolonged sur-
vival.  The pathologic finding of fibrocellular intimal 
proliferation is necessary to confirm the diagnosis of 
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Fig.  4　 Histological examination of a transbronchial lung biopsy 
specimen showed tumor cells in small vessels of the stromal tissue.
Fig.  5　 HRCT scan on Day 28 showed improvement of the 
GGOs,  small granular shadows,  consolidations,  and bronchial wall 
thickenings in bilateral lungs,  and an increase of bilateral pleural 
eﬀusion.
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　　Victoria Blue stain
Fig. 6　 Hematoxylin-eosin stain at the right upper lobe showed 
not only tumor emboli but also ﬁbrocellular intimal proliferation,  and 
recanalization of small pulmonary arterioles.  Victoria Blue stain 
showed the thickening of subintimal elastic ﬁbers.
PTTM; this proliferation is the result of marked activa-
tion of the coagulation system,  either secondary to a 
direct attachment of tumor cells to the endothelium,  or 
secondary to local thrombosis at the surface of tumor 
emboli,  which is the hallmark of angiopathy [1].  
Microangiopathy leads to a diffuse narrowing of the 
pulmonary arterioles and increased vascular resistance,  
resulting in secondary pulmonary hypertension.
PTTM is observed in 1.4-3.3% of consecutive 
autopsy cases of carcinoma [1 , 3 , 5]. The most common 
origin is stomach cancer,  especially the poorly differen-
tiated type; other origins include lung,  breast,  pan-
creas,  and esophagus.  To our knowledge,  four known 
cases of PTTM originating from prostate cancer exist,  
including this case.  Considering the previous reports,  
clinicians who encounter prostate cancer patients with a 
high Gleason score or with a marked rise in PSA,  
should keep the possibility of PTTM in mind [1 , 6 , 7].  
An increasing number of PTTM cases induced by other 
tissue types,  such as urothelial carcinoma,  have been 
reported [8 , 9].
The most common symptoms of PTTM are progres-
sive dyspnea,  coughing and hemoptysis [5].  These 
symptoms are attributed to pulmonary hypertension 
and right-sided heart failure.  PTTM is thus often mis-
diagnosed as idiopathic pulmonary arterial hyperten-
sion.  Chinen et al.  reported that almost half of PTTM 
patients had developed pulmonary hypertension,  or 
“features of increased pulmonary vascular resistance,” 
and these patients died earlier [1 , 4].  The clinical man-
ifestation of end-stage PTTM is pulmonary hyperten-
sion.  An early antemortem diagnosis before the devel-
opment of pulmonary hypertension is thus very important 
[4 , 10].
Nevertheless,  the antemortem diagnosis of PTTM is 
extremely difficult.  Antemortem PTTM has reportedly 
been diagnosed by video-assisted thoracic surgery,  
TBLB,  or CT-guided lung biopsy [8-14].  von Herbay et 
al.  emphasized the presence of both microscopic tumor 
emboli and fibrocellular intimal proliferation in the 
diagnosis of PTTM [1].  As in the present case,  it is 
possible to confirm microscopic tumor emboli by TBLB 
or biopsy,  but it is not possible to confirm the presence 
of fibrocellular intimal proliferation by TBLB or biopsy,  
and it is therefore often difficult to make a definite diag-
nosis.  However,  we strongly suspected PTTM induced 
by prostate cancer in light of the above-described find-
ings.  Because PTTM progressed rapidly if treatment is 
not provided,  we initiated chemotherapy immediately 
before the patient exhibited pulmonary hypertension,  
and he achieved temporary improvement.
The radiologic diagnosis of PTTM has not been 
established because its findings are often minimal and 
nonspecific.  In previous investigations,  chest HRCT 
showed thickened interlobular septa,  diffuse tree-in-
bud opacities,  or ground glass centrilobular micronod-
ules [10 , 11 , 15-17].  These findings are not conclusive 
of PTTM because they can also be found in complicated 
lymphangiosis carcinomatosa [1].  Kayatani et al.  reported 
that PTTM’s ultrafine granular appearance on HRCT 
may be an early indicator of the disease [12].  In our 
patient’s case,  HRCT showed GGO and micronodular 
opacities diffusely spread across bilateral lung fields.  
These findings,  along with the patient’s symptoms,  
resolved temporarily upon chemotherapy.  In addition,  
lymphangiosis carcinomatosa and inflammation of the 
lungs were ruled out at autopsy.  Thus,  findings of 
GGOs and micronodular opacities on HRCT may be 
attributed to the presence of PTTM.
The pathogenesis of PTTM starts with tumor emboli 
to the pulmonary vessels at the microscopic level.  The 
emboli activate the coagulation system and release 
inflammatory mediators [2 , 4 , 10].  In the present case,  
docetaxel might have reduced the cancer cells and 
inhibited the coagulation cascade and inflammation.
In conclusion,  PTTM is an under-recognized diag-
nosis and has an aggressive course once symptoms 
appear.  Early antemortem diagnosis and treatment are 
very important before the patient develops pulmonary 
hypertension.  Therefore,  PTTM should be considered 
in all cancer patients with acute respiratory insuffi-
ciency,  whose CT findings are minimal and nonspe-
cific,  including GGOs and micronodular opacities.
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